A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Inclusion Criteria: * Understand and sign the written informed consent, and comply with the research process schedule during the study period.； * Be aged 40-80 years inclusive at the time of signing the informed consent form； * Have a record of COPD diagnosis for at least 12 months prior to screening； * At screening or after bronchodilator use at the time of the first dose, FEV1 is ≥20% but \<80% of the predicted value； * The FEV1/forced vital capacity (FVC) ratio, measured after the use of bronchodilators at screening or at the time of the first dose, is less than 0.70； * At screening, the Modified Medical Research Council (mMRC) score is ≥2； * At screening, the CAT≥10； * Current smokers or former smokers (who have quit smoking for at least 6 months before Visit 1) with a smoking history of ≥10 pack-years (for example: 20 cigarettes/day for 10 years). At screening, subjects who meet the definition of current smokers will be referred to a smoking cessation clinic； * A chest X-ray or computed tomography (CT) scan within the 3 months prior to screening or during the screening period (before the first dose of study medication) confirms that there are no other clinically significant pulmonary diseases present apart from COPD. Exclusion Criteria: * History of severe allergic reactions or anaphylaxis to biologic agents, or known hypersensitivity to any component of the study drug, or a history of medications or other allergens that the investigator believes would prevent the sub…